Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28456948 | 0.89 | — | — | |
| SCHEMBL11303091 | 0.84 | TDP1 (0.68) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL8989517 | 0.84 | TDP1 (0.68) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL2512363 | 0.84 | TDP1 (0.56) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL137830 | 0.84 | TDP1 (0.56) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL250892 | 0.84 | TDP1 (0.68) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL535994 | 0.84 | TDP1 (0.56) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL17504736 | 0.84 | TDP1 (0.68) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL18322329 | 0.82 | TDP1 (0.54) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL3185056 | 0.82 | TDP1 (0.54) | TDP1MAPK1HSD17B10LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127043-B2 | Purification of immunoglobulins | BIOGEN MA INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127043-B2 | Purification of immunoglobulins | BIOGEN MA INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120053325-A1 | Purification of Immunoglobulins | BIOGEN IDEC MA INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053325-A1 | Purification of Immunoglobulins | BIOGEN IDEC MA INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053325-A1 | Purification of Immunoglobulins | FCGRT, FCGR1A, FCGR3B | TDP1 3439/4885MAPK1 4208/4885HSD17B10 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.